Research ArticlePulmonary fibrosis

Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models

See allHide authors and affiliations

Science Translational Medicine  28 Oct 2020:
Vol. 12, Issue 567, eaay3724
DOI: 10.1126/scitranslmed.aay3724

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Mitigating collagen production

Idiopathic pulmonary fibrosis (IPF) is characterized by deposition of collagen in the lung parenchyma by activated myofibroblasts, cell type exclusively expressing fibroblast activation protein (FAP). Now, Hettiarachchi et al. took advantage of this property and developed a low–molecular weight FAP agonist that could be used to deliver therapeutics to fibrotic tissue. A FAP-targeted phosphatidylinositol 3-kinase (PI3K) inhibitor was shown to reduce collagen production in human IPF lung fibroblasts and had therapeutic effects in a mouse model of IPF. The results suggest that FAP-targeting therapeutics could be effective for treating IPF.

View Full Text

Stay Connected to Science Translational Medicine